BRIEF published on 09/26/2025 at 14:50, 2 months 8 days ago EnVVeno Medical Engages in Virtual Investor Segment Amid FDA Appeal Medical Devices EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Appeal
PRESS RELEASE published on 09/26/2025 at 14:45, 2 months 8 days ago enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment enVVeno Medical Corporation announces CEO Robert Berman's participation in a Virtual Investor segment discussing the supervisory appeal for VenoValve® with FDA FDA EnVVeno Medical VenoValve Virtual Investor Supervisory Appeal
BRIEF published on 09/15/2025 at 14:50, 2 months 19 days ago EnVVeno Medical dépose un recours auprès de la FDA EnVVeno Medical Insuffisance Veineuse Chronique Valve VenoValve Appel Auprès De La FDA Processus Réglementaire
BRIEF published on 09/15/2025 at 14:50, 2 months 19 days ago EnVVeno Medical Pursues FDA Supervisory Appeal EnVVeno Medical VenoValve Chronic Venous Insufficiency Regulatory Process FDA Appeal
PRESS RELEASE published on 09/15/2025 at 14:45, 2 months 19 days ago enVVeno Medical Updates Regulatory Status of VenoValve(R) enVVeno Medical Corporation to file supervisory appeal with FDA regarding not-approvable letter for VenoValve® submission to treat deep venous CVI, aiming to bring innovative solution to patients FDA EnVVeno Medical Corporation VenoValve® Deep Venous Disease Supervisory Appeal
BRIEF published on 08/20/2025 at 13:05, 3 months 15 days ago EnVVeno Medical Receives Not-Approvable Letter from FDA for VenoValve EnVVeno Medical VenoValve FDA Decision Deep Venous Disease Premarket Approval
BRIEF published on 08/20/2025 at 13:05, 3 months 15 days ago EnVVeno Medical reçoit une lettre de non-approbation de la FDA pour VenoValve EnVVeno Medical Valve VenoValve Décision De La FDA Maladie Veineuse Profonde Approbation Préalable À La Mise Sur Le Marché
PRESS RELEASE published on 08/20/2025 at 13:00, 3 months 15 days ago enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) enVVeno Medical received a not-approvable letter from the FDA for VenoValve, citing lacking hemodynamic data and safety concerns. Company to work on new criteria and potential resubmission FDA Medical Device EnVVeno Medical VenoValve CVI
BRIEF published on 08/15/2025 at 15:26, 3 months 20 days ago EnVVeno Medical participera à la série de webinaires financiers Webull EnVVeno Medical Valve VenoValve Maladie Veineuse Profonde Webull Financial Biotechnologie/Technologie Médicale
BRIEF published on 08/15/2025 at 15:26, 3 months 20 days ago EnVVeno Medical to Present at Webull Financial Webinar Series EnVVeno Medical VenoValve Deep Venous Disease Webull Financial Biotech/MedTech
Published on 12/05/2025 at 02:35, 6 hours 43 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 8 hours 18 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 13 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 18 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:05, 13 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 33 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 33 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 36 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 3 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 18 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
